IRMA-International.org: Creator of Knowledge
Information Resources Management Association
Advancing the Concepts & Practices of Information Resources Management in Modern Organizations

From Bench to Bedside: BACE1, Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1, From Basic Science to Clinical Investigation

From Bench to Bedside: BACE1, Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1, From Basic Science to Clinical Investigation
View Sample PDF
Author(s): Yong Shen (Center for Advanced Therapeutic Strategies for Brain Disorders, Raskamp Institute, USA)
Copyright: 2013
Pages: 7
Source title: Bioinformatics: Concepts, Methodologies, Tools, and Applications
Source Author(s)/Editor(s): Information Resources Management Association (USA)
DOI: 10.4018/978-1-4666-3604-0.ch017

Purchase


Abstract

Alzheimer’s disease (AD) is a constantly progressive and highly complex neurodegenerative disease, and there are many ways to molecularly characterize the various stages. Morphologically, AD patients are characterized by neurofibrillar abnormalities associated with pathological hyperphosphorylation of tau protein, and deposits of ß– amyloid peptides (Aß). There is an overwhelming amount of information to support the hypothesis that generation, formation, and ß-amyloid deposits play key mechanistic roles in the early development of AD. It is known that the cause of early-onset familial AD (FAD) is due to mutations in three genes which cause an increase in the production of the toxic peptide, Aß42. The molecules that cause the proteolytic activities of beta and gamma secretase, two proteases that free the Aß-peptide by endoproteolyzing APP, have recently been discovered. Homologous to BACE1, BACE2 was also a recent discovery (Lin et al, 2000; Vassar et al, 1999; Yan et al, 1999), and together these two enzymes make up a new family of transmembrane aspartic proteases. The key enzyme, BACE1, initiates the formation of Aß, represents a candidate biomarker, as well as a drug target for AD, exhibit all the functional properties of ß–secretase. This chapter will review the biology of BACE1 and focus attention to BACE1 as a candidate biomarker for the early detection, prediction, and biological activity in AD.

Related Content

Alessandra Lima da Silva, Diego Mariano, Mariana Parise, Angie L. A. Puelles, Tatiane Senna Bialves, Luana Luiza Bastos, Lucas Santos, Rafael Pereira Lemos. © 2025. 22 pages.
Seyyed Mohammad Amin Mousavi Sagharchi, Mohsen Sheykhhasan, Atousa Ghorbani, Elina Afrazeh, Naresh Poondla, Naser Kalhor, Hamid Tanzadehpanah, Hanie Mahaki, Hamed Manoochehri. © 2025. 46 pages.
Eduarda Guimarães Sousa, Lucas Gabriel Rodrigues Gomes, Fernanda Diniz Prates, Talita Pereira Gomes, Gabriel Camargos Gomes, Janaíne Aparecida de Paula, Ana Lua de Oliveira Vinhal, Bernardo Buhr Alves Mendonça, Mariana Letícia Costa Pedrosa, Luiza Pereira Reis, Aline Ferreira Maciel de Oliveira, Marcus Vinicius Canário Viana, Arun Kumar Jaiswal, Siomar de Castro Soares, Vasco Ariston de Carvalho Azevedo. © 2025. 38 pages.
Diego Mariano, Lucas Moraes dos Santos, Raquel Cardoso de Melo-Minardi. © 2025. 30 pages.
Alessandra G. Cioletti, Frederico C. Carvalho, Lucas M. Dos Santos, Raquel C. M. Minardi. © 2025. 32 pages.
Leandro Morais de Oliveira, Luana Luiza Bastos, Vivian Morais Paixão, Leticia Aparecida Gontijo, Tatiane Senna Bialves, Diego Mariano, Raquel Cardoso de Melo Minardi. © 2025. 40 pages.
Angie Atoche Puelles, Luana Luiza Bastos, Vivian Morais Paixão, Sheila Cruz Araujo, Raquel Cardoso de Melo Minardi. © 2025. 28 pages.
Body Bottom